Skip to main content

Table 1 Key parameters for the model of adjuvant treatment of regional breast cancer with ACTH and TCH

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

Variable Formula Best estimate SA range Distribution Source
Probability      
–ACTH
RR
  0.837    [14,15,16,17,18]
OS
TTP
  44.3
7.2
   
DOR   5.6    
Stable → Stable (ACss) 1-ACsp-ACsr 0.401 0.3208–0.4812 Beta  
Stable → Remission (ACsr) 1-exp(−RR/3) 0.243 0.1944–0.2916 Beta  
Stable → Relapse(ACsp) ACrp*4 0.356 0.2848–0.4272 Beta  
Remission → Remission (ACrr) 1-ACrp 0.911 0.7288–1.0000 Beta  
Remission → Relapse (ACrp) exp(− 0.75*In (2)/(5.6)) 0.089 0.0712–0.1068 Beta  
Relapse → Relapse (ACpp) 1-ACpd 0.986 0..7888–1.0000 Beta  
Relapse → Death (ACpd) exp(− 0.75*In (2)/(44.3–7.2)) 0.014 0.0112–0.0168 Beta  
−TCH
RR
  0.704    [19,20,21,22,23]
OS
TTP
  35
10.35
   
DOR   4    
Stable → Stable (TCss) 1-TCsp-TCsr 0.311 0.2488–0.3732 Beta  
Stable → Remission(TCsr) 1-exp(− RR/3) 0.209 0.1672–0.2508 Beta  
Stable → Relapse(TCsp) TCrp*4 0.48 0.384–0.576 Beta  
Remission → Remission (TCrr) 1-TCrp 0.88 0.704–1.0000 Beta  
Remission → Relapse (TCrp) exp(− 0.75*In (2)/4.2)) 0.12 0.096–0.144 Beta  
Relapse → Relapse(TCpp) 1-TCpd 0.979 0.7832–1.0000 Beta  
Relapse → Death(TCpd) exp(− 0.75*In (2)/(35–10.35)) 0.021 0.0168–0.0252 Beta  
Discount rate for costs and QALYs   5% per year    [24]
Health state utilities      [13]
No recurrence (chemotherapeutic period)   0.74 0.592–0.888 Beta  
No recurrence (after chemotherapy)   0.94 0.752–1.000 Beta  
local recurrence (in the first year)   0.74 0.592–0.888 Beta  
remission   0.85 0.68–1.000 Beta  
Relapse   0.5 0.4–0.6 Beta  
  1. OS overall survival, DOR duration of response, TTP time to progression
\